RxDoctor Payments DataLook up a doctor →

Andrew Cope, DO

Family Medicine · Newton, IANPI 1912134693

Payments from drug & device makers

$8,687in general payments, 2019–2025

Across 624 payments — averaging $13.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Boehringer Ingelheim$1K
  • AbbVie$727
  • Novo Nordisk$583
  • Lilly USA, LLC$471
  • GSK$437
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$8,63699%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,687 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$93,857
Medicare patients
424
Services billed
1,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$73,997
FarxigaDapagliflozin Propanediol65$55,705
OzempicSemaglutide36$41,296
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$30,411
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$20,787
JardianceEmpagliflozin17$18,086
Tresiba Flextouch U-100Insulin Degludec30$15,300
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$13,920
MounjaroTirzepatide11$11,188
MyrbetriqMirabegron13$11,171
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,854
GemtesaVibegron18$7,967
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$6,345
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$4,016
Novolog FlexpenInsulin Aspart24$3,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,428$73,99772 claims
AstraZenecaFarxiga, Breztri Aerosphere$432$64,55977 claims
GSKTrelegy Ellipta, Anoro Ellipta$437$51,19967 claims
Novo NordiskOzempic$583$41,29636 claims
Boehringer IngelheimJardiance, Stiolto Respimat$1,112$32,00640 claims
Lilly USA, LLCMounjaro$471$11,18811 claims
Astellas Pharma US IncMyrbetriq$248$11,17113 claims
Sumitomo Pharma America, Inc.Gemtesa$17$7,96718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Newton

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →